Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0055

Scientific exchange · Dr. William Vogel

17 Jan 2026 · In person · Dr. William Vogel, UCLH · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0055—

Capture insight from this engagement

Location: UCLH
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Sequencing after progression
Elderly / ECOG 2 patients

Scientific content used

VOYAGE-1 pivotal data summary
VTX core scientific deck v3.2

Questions raised

No questions recorded.

Notes

Scientific exchange with pathologist at UCLH. Discussed pd-l1 testing turnaround, sequencing after progression, elderly / ecog 2 patients.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 5
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0055

Audit history (0)

All create, update and approval events for this record

No audit events in sample data